-
To promote the innovation of the source of new cancer drug creation, the first domestic medical enterprises linked top-level resource platform debuted.
Time of Update: 2020-10-27
(Health Times reporter Jing Chao intern reporter Gao Xiaoxuan ) " The transformation of Chinese pharmaceutical development technology, 46% from enterprises, less than 10% from clinical. The transforma
-
TERT and DNMT1 express the sensitivity of predictive gliomas to Tesitham.
Time of Update: 2020-10-24
study Methods The authors conducted in-body experimental studies of single DAC or in-body IDH1 mutant and wild glioma cell line in a single DAC or in union with telomerase inhibitors after regulating the expression and activity of TRT and DNMT1.
-
Advances have been made in the study of tumor immunotherapy system based on bacterial outer membrane cysts.
Time of Update: 2020-10-24
Recently, a research team led by Ma Guangguang and Wei Wei, researchers at the Institute of Process Engineering of the Chinese Academy of Sciences, discovered the potential of simple bacterial outer membrane vesicles (OMVs) naturally secreted by bacteria in regulating the micro-environment of tumor immunosuppression, and adopted bionic mineralization strategies to make OMVs surfaces grow "invisible" calcium phosphate shells to avoid toxic side effects caused by simple OMVs intravenous injections.
-
Heavy! Dabohua ® (Lytoxi single anti-injection) has been officially approved for listing in China.
Time of Update: 2020-10-24
Dabohua® (Lytoxi monoantigen injection) is a recombinant human-rat-embedded anti-CD20 monoclonal antibody injection jointly developed by Lilly Pharmaceuticals and Cynda Bio, and the launch of Dabohua ® (Lytoxi monoantigen injection) will provide higher quality and more affordable lysoxi monoantigen injections to more Chinese patients.
-
Sci Adv: A new 3D tumor model developed in the lab may help improve treatment for ovarian cancer.
Time of Update: 2020-10-23
Photo Source: Alvaro Mata Researchers now need an improved version of the 3D cancer model to study tumor growth, progression, and response to new therapies in ovarian cancer patients, with 90 percent of successful cancer treatments tested in preclinical trials failing in early clinical trials and less than 5 percent of cancer drugs successfully used in clinical trials, and preclinical trials relying on 2D lab-grown cell cultures and animal models to predict patient responses to treatments.
-
Nat Cancer: Immunotherapy treats rare eye cancers.
Time of Update: 2020-10-23
Next, to test the safety and benefits of targeting GD2, the researchers injected CAR-T, a molecule identified with the molecule, into the retina of mice that had developed retinal cell tumor cancer cells, and found that the therapy delayed tumor development but did not eradicate the tumor.
-
An IDH1/2 wild WHO IV. class diffuse star cell glue with GBM molecular characteristics...
Time of Update: 2020-10-23
results compared 71 patients with IDH1/2 wild WHO IV.class glioma with typical clinical, imaging and histological characteristics of LGG with OS in 197 patients with IDH1/2 wild glioblastoma.
-
elife: A new mechanism for T-cells to fight cancer.
Time of Update: 2020-10-22
"Scientists used to think that T cells that kill cancer identify tumors by randomly searching for or following chemical traces produced by other intermediate immune cells," said lead author Jorge Luis Galeano Niño of .pixabay.com.
-
The main genetic differences of HGG are shown in different MRI and MRS imaging.
Time of Update: 2020-10-22
study included 79 HGG patients who analyzed the expression levels of IDH, ATRX, Ki-67 and p53 through immunogasification, applied MRI to examine tumor imaging performance and MRS to evaluate metabolic and immersion characteristics, and further clarified the relationship between HGG imaging characteristics and molecular science.
-
Based on MRS analysis, a new radiotherapy plan for GBM was developed.
Time of Update: 2020-10-22
clinical trials based on magnetic resonance wave spectrometry (MRS)CHO/NAA ratios for "dose mapping" - SPECTRO-GLIO (NCT01507506), published in the February 2019 issue of BMC Cancer.
-
Progress has been made in anti-tumor immunotherapy.
Time of Update: 2020-10-22
although researchers have developed a number of combination therapies to increase sensitivity ICT, but still can not achieve better tumor treatment results.
-
Oncotarget: The production of a new microRNA or prostetin E2 that can target lung cancer cells is expected to help treat lung cancer!
Time of Update: 2020-10-22
October 15, 2020 // -- In a recent study published in the international journal Oncotarget, scientists from rutgers' Institute of Biomedical and Health Sciences and others found that high levels of miR-708 expression were directly related to survival rates in patients with pulmonary squamous cell carcinoma, and that miR-708 inhibits the production of PGE2 by inhibiting expressions of COX-2 and mPGES-1 in lung cancer cells.
-
JAMA: Effects of continuous counseling and smoking cessation drugs on smoking rate in patients with smoking tumors.
Time of Update: 2020-10-21
six-month bio-confirmed withdrawal rate was 34.5% in the intensive treatment group (n-51), compared with 21.5% in the standard treatment group (n-29, with a difference of 13.0%; advantage ratio: 1.92).
-
FDA approves Merck's KEYTRUDA (Pam monoanti) for the treatment of adult patients with relapsed or refractic classic Hodgkin's lymphoma (cHL).
Time of Update: 2020-10-21
Merck announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of Merck's anti-PD-1 single-anti-KEYTRUDA for adult patients with relapsed or refractic classic Hodgkin's lymphoma (cHL) progressing after first-line treatment.
the approval of KEYTRUDA may help these patients achieve better results.
-
NEJM: Pani monoantigen-related eyelash elongity - case reported.
Time of Update: 2020-10-21
months ago, she began receiving the skin growth factor recipient (EGFR) inhibitor Pani monoantigen to treat cancer.
if it develops into eyelash elongation, it is usually noticed in the first few months of treatment, just like in the patient.
-
Br J Cancer: Microdrop Digital PCR Technology: TRT Promoter Area Mutation Detection "Sharp" in Breast Fiber Epithelirsty Tumors
Time of Update: 2020-10-21
compared TERTp mutation analysis between ddPCR and Sanger Sequencing collected FA and PT samples from 82 patients who underwent surgery at the University of Tokyo Medical Department Hospital between 2005 and 2016.
2/17 (12%) of the 17 Sanger sequencing samples tested positive for the TERTp mutation.
-
Nat Cell Biol: Is it cancer-promoting or anti-cancer? PD-L1 has an unknown side.
Time of Update: 2020-10-21
same time, the study also reported that nuclear PD-L1 was able to raise immune checkpoint genes such as PD-L2 and VISTA in tumor cells, thereby promoting resistance of tumor cells to PD1/PD-L1 blocking therapy.
-
Yiyi Shenzhou completed a new round of financing to further expand the gene cell drug pipeline.
Time of Update: 2020-10-21
"Over the past few years, China's gene cell drug industry has developed rapidly and accumulated a number of outstanding innovations," said Dr. He Wei, founder and CEO of Beijing Yiyi Shenzhou Pharmaceutical Technology Co., Ltd.
-
Brit J Cancer: The prognostic significance of the ratio of pre-radiation neutral granulocytes to lymphocytes in patients with oral pharyngeal cancer.
Time of Update: 2020-10-21
A recent study published in British Journal of Cancer, an authoritative journal in the field of oncology, aims to assess the prognostic value of the ratio of neutral granulocytes to lymphocytes (NLRs) in patients with oral and pharynx cancer.
-
Real-world studies have shown that adding cell therapy PROVNGE (sipuleucel-T) to advanced prostate cancer treatment options can extend the medium survival by 14.5 months.
Time of Update: 2020-10-21
Dendreon Pharmaceuticals conducted a real-world study of more than 6,000 male patients with metastatic degenerative degenerative prostate (mCRPC), adding cell therapy PROFENGE (sipuleucel-T) to commonly prescribed drugs (abiraterone acetate and enzalutamide) to reduce the risk of death by 41% and extend the medium total survival period (OS) by 14.5 months.
